TY - JOUR
T1 - T cell– and monocyte-specific RNA-sequencing analysis in septic and nonseptic critically ill patients and in patients with cancer
AU - Washburn, Michael L.
AU - Wang, Zhang
AU - Walton, Andrew H.
AU - Peter Goedegebuure, S.
AU - Figueroa, David J.
AU - van Horn, Stephanie
AU - Grossman, Julie
AU - Remlinger, Katja
AU - Madsen, Heather
AU - Brown, James
AU - Srinivasan, Roopa
AU - Wolf, Amaya I.
AU - Berger, Scott B.
AU - Yi, Victoria N.
AU - Hawkins, William G.
AU - Fields, Ryan C.
AU - Hotchkiss, Richard S.
N1 - Publisher Copyright:
Copyright © 2019 by The American Association of Immunologists.
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Sepsis is characterized as life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The purpose of this investigation was to determine the differential effect of sepsis on innate versus adaptive immunity, in humans, by examining RNA expression in specific immune cell subsets, including monocytes/macrophages and CD4 and CD8 T cells. A second aim was to determine immunosuppressive mechanisms operative in sepsis that might be amenable to immunotherapy. Finally, we examined RNA expression in peripheral cells from critically ill nonseptic patients and from cancer patients to compare the unique immune response in these disorders with that occurring in sepsis. Monocytes, CD4 T cells, and CD8 T cells from septic patients, critically ill nonseptic patients, patients with metastatic colon cancer, and healthy controls were analyzed by RNA sequencing. Sepsis induced a marked phenotypic shift toward downregulation of multiple immune response pathways in monocytes suggesting that impaired innate immunity may be fundamental to the immunosuppression that characterizes the disorder. In the sepsis cohort, there was a much more pronounced effect on gene transcription in CD4 T cells than in CD8 T cells. Potential mediators of sepsis-induced immunosuppression included Arg-1, SOCS-1, and SOCS-3, which were highly upregulated in multiple cell types. Multiple negative costimulatory molecules, including TIGIT, Lag-3, PD-1, and CTLA-4, were also highly upregulated in sepsis. Although cancer had much more profound effects on gene transcription in CD8 T cells, common immunosuppressive mechanisms were present in all disorders, suggesting that immunoadjuvant therapies that are effective in one disease may also be efficacious in the others.
AB - Sepsis is characterized as life-threatening organ dysfunction caused by a dysregulated host immune response to infection. The purpose of this investigation was to determine the differential effect of sepsis on innate versus adaptive immunity, in humans, by examining RNA expression in specific immune cell subsets, including monocytes/macrophages and CD4 and CD8 T cells. A second aim was to determine immunosuppressive mechanisms operative in sepsis that might be amenable to immunotherapy. Finally, we examined RNA expression in peripheral cells from critically ill nonseptic patients and from cancer patients to compare the unique immune response in these disorders with that occurring in sepsis. Monocytes, CD4 T cells, and CD8 T cells from septic patients, critically ill nonseptic patients, patients with metastatic colon cancer, and healthy controls were analyzed by RNA sequencing. Sepsis induced a marked phenotypic shift toward downregulation of multiple immune response pathways in monocytes suggesting that impaired innate immunity may be fundamental to the immunosuppression that characterizes the disorder. In the sepsis cohort, there was a much more pronounced effect on gene transcription in CD4 T cells than in CD8 T cells. Potential mediators of sepsis-induced immunosuppression included Arg-1, SOCS-1, and SOCS-3, which were highly upregulated in multiple cell types. Multiple negative costimulatory molecules, including TIGIT, Lag-3, PD-1, and CTLA-4, were also highly upregulated in sepsis. Although cancer had much more profound effects on gene transcription in CD8 T cells, common immunosuppressive mechanisms were present in all disorders, suggesting that immunoadjuvant therapies that are effective in one disease may also be efficacious in the others.
UR - http://www.scopus.com/inward/record.url?scp=85072628439&partnerID=8YFLogxK
U2 - 10.4049/jimmunol.1900560
DO - 10.4049/jimmunol.1900560
M3 - Article
C2 - 31484735
AN - SCOPUS:85072628439
SN - 0022-1767
VL - 203
SP - 1897
EP - 1908
JO - Journal of Immunology
JF - Journal of Immunology
IS - 7
ER -